580 related articles for article (PubMed ID: 28807915)
1. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
[TBL] [Abstract][Full Text] [Related]
2. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for
Bang CS; Lim H; Jeong HM; Shin WG; Choi JH; Soh JS; Kang HS; Yang YJ; Hong JT; Shin SP; Suk KT; Lee JJ; Baik GH; Kim DJ
Gut Microbes; 2020 Sep; 11(5):1314-1323. PubMed ID: 32362221
[TBL] [Abstract][Full Text] [Related]
3. Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management.
Pabón-Carrasco M; Keco-Huerga A; Castro-Fernández M; Saracino IM; Fiorini G; Vaira D; Pérez-Aísa Á; Tepes B; Jonaitis L; Voynovan I; Lucendo AJ; Lanas Á; Martínez-Domínguez SJ; Almajano EA; Rodrigo L; Vologzanina L; Brglez Jurecic N; Denkovski M; Bujanda L; Abdulkhakov RA; Huguet JM; Fernández-Salazar L; Alcaide N; Velayos B; Silkanovna Sarsenbaeva A; Zaytsev O; Ilchishina T; Barrio J; Bakulin I; Perona M; Alekseenko S; Romano M; Gravina AG; Núñez Ó; Gómez Rodríguez BJ; Ledro-Cano D; Pellicano R; Bogomolov P; Domínguez-Cajal M; Almela P; Gomez-Camarero J; Bordin DS; Gasbarrini A; Kupčinskas J; Cano-Català A; Moreira L; Nyssen OP; Mégraud F; O'Morain C; Gisbert JP;
United European Gastroenterol J; 2024 Feb; 12(1):122-138. PubMed ID: 38050339
[TBL] [Abstract][Full Text] [Related]
4. Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole.
Gisbert JP; Gisbert JL; Marcos S; Grávalos RG; Carpio D; Pajares JM
Aliment Pharmacol Ther; 1999 Oct; 13(10):1311-6. PubMed ID: 10540045
[TBL] [Abstract][Full Text] [Related]
5. Fourteen-day vonoprazan-based bismuth quadruple therapy for H. pylori eradication in an area with high clarithromycin and levofloxacin resistance: a prospective randomized study (VQ-HP trial).
Tungtrongchitr N; Bongkotvirawan P; Ratana-Amornpin S; Siramolpiwat S; Eiamsitrakoon T; Gamnarai P; Wongcha-Um A; Yamaoka Y; Pawa KK; Vilaichone RK
Sci Rep; 2024 Apr; 14(1):8986. PubMed ID: 38637591
[TBL] [Abstract][Full Text] [Related]
6. Colloidal bismuth pectin: an alternative to bismuth subcitrate for the treatment of Helicobacter pylori--positive duodenal ulcer.
Nie Y; Li Y; Wu H; Sha W; Du H; Dai S; Wang H; Li Q
Helicobacter; 1999 Jun; 4(2):128-34. PubMed ID: 10382127
[TBL] [Abstract][Full Text] [Related]
7. Empiric Versus Clarithromycin Resistance-Guided Therapy for Helicobacter pylori Based on Polymerase Chain Reaction Results in Patients With Gastric Neoplasms or Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Randomized Controlled Trial.
Kim JL; Cho SJ; Chung SJ; Lee A; Choi J; Chung H; Kim SG
Clin Transl Gastroenterol; 2020 Sep; 11(9):e00194. PubMed ID: 33094958
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies.
Realdi G; Dore MP; Piana A; Atzei A; Carta M; Cugia L; Manca A; Are BM; Massarelli G; Mura I; Maida A; Graham DY
Helicobacter; 1999 Jun; 4(2):106-12. PubMed ID: 10382124
[TBL] [Abstract][Full Text] [Related]
9. Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection.
Graham DY; Hoffman J; el-Zimaity HM; Graham DP; Osato M
Aliment Pharmacol Ther; 1997 Oct; 11(5):935-8. PubMed ID: 9354203
[TBL] [Abstract][Full Text] [Related]
10. Annual eradication rate of bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: A 15-year prospective study at a tertiary hospital in Korea.
Yoon K; Kim N; Lee JW; Yoon H; Shin CM; Park YS; Lee DH
Helicobacter; 2020 Jun; 25(3):e12685. PubMed ID: 32141173
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of twice a day, bismuth-containing quadruple therapy using high-dose tetracycline and metronidazole for second-line Helicobacter pylori eradication.
Kim JY; Lee SY; Kim JH; Sung IK; Park HS
Helicobacter; 2020 Apr; 25(2):e12683. PubMed ID: 32074663
[TBL] [Abstract][Full Text] [Related]
12. Four-day, twice daily, quadruple therapy with amoxicillin, clarithromycin, tinidazole and omeprazole to cure Helicobacter pylori infection: a pilot study.
Calvet X; Titó L; Comet R; García N; Campo R; Brullet E
Helicobacter; 2000 Mar; 5(1):52-6. PubMed ID: 10672052
[TBL] [Abstract][Full Text] [Related]
13. 14-day tailored PCR-guided triple therapy versus 14-day non-Bismuth concomitant quadruple therapy for Helicobacter pylori eradication: A multicenter, open-label randomized noninferiority controlled trial.
Amiot A; Hacoon J; Heluwaert F; Mion F; Lamarque D; Moussata D; Mimouni M; Delchier JC; Durand-Zaleski I; Audureau E; Bastuji-Garin S;
Helicobacter; 2024; 29(2):e13076. PubMed ID: 38680067
[TBL] [Abstract][Full Text] [Related]
14. Modified quadruple therapy or bismuth-containing quadruple therapy in the first-line treatment of Helicobacter pylori in Turkey.
Yozgat A; Kasapoğlu B; Demirci S; Coşkun Sökmen F
Rev Esp Enferm Dig; 2021 Jul; 113(7):490-493. PubMed ID: 33233910
[TBL] [Abstract][Full Text] [Related]
15. One-week ranitidine bismuth citrate versus colloidal bismuth subcitrate-based anti-Helicobacter triple therapy: a prospective randomized controlled trial.
Kung NN; Sung JJ; Yuen NW; Li TH; Ng PW; Lai WM; Lui YH; Lam KN; Choi CH; Leung EM
Am J Gastroenterol; 1999 Mar; 94(3):721-4. PubMed ID: 10086657
[TBL] [Abstract][Full Text] [Related]
16. Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial.
Kim YI; Lee JY; Kim CG; Park B; Park JY; Choi IJ
BMC Gastroenterol; 2021 Mar; 21(1):95. PubMed ID: 33653284
[TBL] [Abstract][Full Text] [Related]
17. Efficacy comparison of 7- and 14-day P-CAB based bismuth-containing quadruple regimen with PPI based bismuth-containing quadruple regimen for Helicobacter pylori infection: rationale and design of an open-label, multicenter, randomized controlled trial.
Oh CK; Lim H; Seo SI; Lee SP; Bang CS; Shin WG; Kim JB; Jang HJ; Baik GH
BMC Gastroenterol; 2023 Dec; 23(1):453. PubMed ID: 38129806
[TBL] [Abstract][Full Text] [Related]
18. Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication.
Treiber G; Ammon S; Schneider E; Klotz U
Helicobacter; 1998 Mar; 3(1):54-8. PubMed ID: 9546119
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of a bismuth-based quadruple therapy regimen for
Alsohaibani F; Alquaiz M; Alkahtani K; Alashgar H; Peedikayil M; AlFadda A; Almadi M
Saudi J Gastroenterol; 2020; 26(2):84-88. PubMed ID: 32295933
[TBL] [Abstract][Full Text] [Related]
20. 14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line Helicobacter pylori Treatment.
Luo L; Ji Y; Yu L; Huang Y; Liang X; Graham DY; Lu H
Dig Dis Sci; 2020 Dec; 65(12):3639-3646. PubMed ID: 32020360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
